ETC 1001
Alternative Names: ESP-31015; ETC-1001Latest Information Update: 10 Dec 2007
At a glance
- Originator Esperion Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
- 22 Oct 2003 Esperion has completed enrolment in the ETC 1001-001 trial
- 16 Jul 2003 Phase-I clinical trials in Atherosclerosis in USA (PO)